Stocks › HALO
HALOZYME THERAPEUTICS, INC.
HALO·Nasdaq·
United States·USD
United States·USD$109.72
+1.41 (+1.30%)
Close · Oct 6, 2026 · Close Prices from Tiingo.com
HALO
HALOZYME THERAPEUTICS, INC. · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
HALOS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair
Congressional Trades
Recent trades of HALO by members of U.S. Congress · 10 on record · 1 in the last 12 months
Whale Activity
Position changes in HALO reported for 2026-09-30 by 2 tracked institutional filers
- Increased0
- New0
- Held0
- Decreased0
- Closed0
- No prior filing2
| Filer | Shares | Value | Change |
|---|---|---|---|
| CONGRESS ASSET MANAGEMENT CO | 2.3M | $251.9M | — |
| Pacific Wealth Management | 2,184 | $241K | — |
KeyVex tracks a curated set of large 13F filers plus the largest positions in recent filings, so this is a sample of institutional activity, not the whole market.
Insider Trading
Net shares bought (+) or sold (−) on the open market by HALO insiders, by quarter · Form 4
Recent Insider Transactions
2,125 transactions on record · newest first
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| Posard Matthew L.Director · Director | Sale | −730 | $107.17 | $78K | Oct 1, 2026 | Form 4 ↗ |
| Posard Matthew L.Director · Director | Sale | −3,300 | $108.45 | $358K | Oct 1, 2026 | Form 4 ↗ |
| Posard Matthew L.Director · Director | Sale | −1,100 | $109.57 | $121K | Oct 1, 2026 | Form 4 ↗ |
| Posard Matthew L.Director · Director | Sale | −100 | $110.04 | $11K | Oct 1, 2026 | Form 4 ↗ |
| Posard Matthew L.Director · Director | Sale | −8,896 | $108.04 | $961K | Sep 16, 2026 | Form 4 ↗ |
| Posard Matthew L.Director · Director | Sale | −4,000 | $108.99 | $436K | Sep 16, 2026 | Form 4 ↗ |
| Posard Matthew L.Director · Director | Sale | −3,100 | $106.13 | $329K | Sep 16, 2026 | Form 4 ↗ |
| Posard Matthew L.Director · Director | Sale | −3,000 | $106.83 | $320K | Sep 16, 2026 | Form 4 ↗ |
| Torley HelenPRESIDENT AND CEO · Director | Sale | −4,508 | $107.55 | $485K | Sep 11, 2026 | Form 4 ↗ |
| Torley HelenPRESIDENT AND CEO · Director | Sale | −15.5K | $107.15 | $1.7M | Sep 11, 2026 | Form 4 ↗ |
| Torley HelenPRESIDENT AND CEO · Director | Sale | −5,412 | $107.58 | $582K | Sep 10, 2026 | Form 4 ↗ |
| Torley HelenPRESIDENT AND CEO · Director | Sale | −14.6K | $107.01 | $1.6M | Sep 10, 2026 | Form 4 ↗ |
| Torley HelenPRESIDENT AND CEO · Director | Sale | −6,596 | $107.82 | $711K | Sep 9, 2026 | Form 4 ↗ |
| Torley HelenPRESIDENT AND CEO · Director | Sale | −13.3K | $107.22 | $1.4M | Sep 9, 2026 | Form 4 ↗ |
| Torley HelenPRESIDENT AND CEO · Director | Sale | −100 | $108.67 | $11K | Sep 9, 2026 | Form 4 ↗ |
| Torley HelenPRESIDENT AND CEO · Director | Sale | −9,600 | $107.22 | $1.0M | Aug 19, 2026 | Form 4 ↗ |
| Torley HelenPRESIDENT AND CEO · Director | Sale | −7,200 | $106.36 | $766K | Aug 19, 2026 | Form 4 ↗ |
| Torley HelenPRESIDENT AND CEO · Director | Sale | −3,200 | $107.77 | $345K | Aug 19, 2026 | Form 4 ↗ |
| Torley HelenPRESIDENT AND CEO · Director | Sale | −9,400 | $104.87 | $986K | Aug 18, 2026 | Form 4 ↗ |
| Torley HelenPRESIDENT AND CEO · Director | Sale | −5,703 | $103.08 | $588K | Aug 18, 2026 | Form 4 ↗ |
Fund Holders
Mutual funds and ETFs holding HALO · SEC Form N-PORT
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| iShares Core S&P Mid-Cap ETF iShares Trust | 4.1M | $317.7M | 0.26% | Jun 30, 2026 |
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 3.8M | $294.5M | 0.01% | Jun 30, 2026 |
| VANGUARD SMALL-CAP INDEX FUND VANGUARD INDEX FUNDS | 2.7M | $213.0M | 0.11% | Jun 30, 2026 |
| VANGUARD SMALL-CAP GROWTH INDEX FUND VANGUARD INDEX FUNDS | 1.6M | $122.6M | 0.26% | Jun 30, 2026 |
| Disciplined Value Mid Cap Fund John Hancock Funds III | 1.4M | $112.0M | 0.48% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF SPDR SERIES TRUST | 1.4M | $110.5M | 1.03% | Jun 30, 2026 |
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 1.4M | $106.4M | 0.11% | Jun 30, 2026 |
| First Trust NYSE Arca Biotechnology Index Fund First Trust Exchange-Traded Fund | 1.1M | $87.6M | 3.11% | Jun 30, 2026 |
| Invesco Discovery Fund AIM Counselor Series Trust (Invesco Counselor Series Trust) | 1.3M | $83.4M | 1.07% | May 31, 2026 |
| FULLERTHALER BEHAVIORAL SMALL-CAP GROWTH Capitol Series Trust | 968.8K | $75.8M | 1.23% | Jun 30, 2026 |
Mutual funds and ETFs whose N-PORT filings list HALO's shares (CUSIP 40637H109), each fund at its latest report since Mar 7, 2026, largest positions first. Bonds, options and short positions are left out.
Activist & Passive Stakes
Schedule 13D / 13G beneficial-ownership filings
No 13D/13G beneficial-ownership filings on record.
Corporate Lobbying
Estimated quarterly lobbying spending reported under the LDA, filings naming halozyme therapeutics as client
- FORBES-TATEHALOZYME THERAPEUTICS, INC. · 2026 Q2 · MMM, HCR$80K
Filing ↗ - FORBES-TATEHALOZYME THERAPEUTICS, INC. · 2026 Q1 · HCR, MMM$70K
Filing ↗ - FORBES-TATEHALOZYME THERAPEUTICS, INC. · 2025 Q4 · HCR, MMM$60K
Filing ↗ - FORBES-TATEHALOZYME THERAPEUTICS, INC. · 2025 Q3 · HCR, MMM$60K
Filing ↗ - FORBES-TATEHALOZYME THERAPEUTICS, INC. · 2025 Q2 · HCR$60K
Filing ↗
Government Contracts
Federal awards to HALOZYME THERAPEUTICS, INC. · USAspending
No federal contract awards found for HALOZYME THERAPEUTICS, INC..
U.S. Patents
Recent USPTO applications naming HALOZYME THERAPEUTICS, INC.
No USPTO patent applications found for HALOZYME THERAPEUTICS, INC..
Annual Financials
From HALO's 10-K filings · XBRL
No annual XBRL figures on record for HALO. KeyVex's fundamentals cover about 130 large companies so far.
Stock Splits
Every split and reverse split in the price history
No stock splits in HALO's price history.
Material Events (8-K)
Corporate events filed with the SEC
- 8-K · Items 5.02Officer / director changeSep 30, 2026
EDGAR ↗ - 8-K · Items 1.01, 2.03, 3.02, 9.01Material agreement · Direct financial obligation · Unregistered sale of equitySep 22, 2026
EDGAR ↗ - 8-K · Items 8.01, 9.01Other eventsSep 18, 2026
EDGAR ↗ - 8-K · Items 8.01, 9.01Other eventsSep 16, 2026
EDGAR ↗ - 8-K · Items 5.02Officer / director changeAug 18, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsAug 6, 2026
EDGAR ↗ - 8-K · Items 5.02Officer / director changeJul 2, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsMay 11, 2026
EDGAR ↗ - 8-K · Items 5.07Shareholder voteMay 7, 2026
EDGAR ↗
About HALOZYME THERAPEUTICS, INC.
From SEC EDGAR company records
Industry (SIC 2836)Biological Products, (No Diagnostic Substances)
SectorHealthcare
HeadquartersSAN DIEGO, CA
IncorporatedDE
SEC CIK0001159036 ↗
Former namesHALOZYME THERAPEUTICS INC, GLOBAL YACHT SERVICES INC